(Q80297582)

PubMed publication ID

16985923

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985923%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

title

Comparison of clinical trials with finasteride and dutasteride (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472914&resulttype=core&format=json

10 May 2020

1 reference

J Curtis Nickel

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472914&resulttype=core&format=json

10 May 2020

publication date

1 January 2004

1 reference

PubMed publication ID

16985923

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16985923%20AND%20SRC:MED&resulttype=core&format=json

30 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472914&resulttype=core&format=json

10 May 2020

volume

6 Suppl 9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472914&resulttype=core&format=json

10 May 2020

page(s)

S31-9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472914&resulttype=core&format=json

Safety and tolerability of the dual 5alpha-reductase inhibitor dutasteride in the treatment of benign prostatic hyperplasia

10 May 2020

cites work

1 reference

12 December 2020

Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia

1 reference

12 December 2020

5alpha-reductase activity in the prostate

1 reference

12 December 2020

Discontinuation of alpha-blockade after initial treatment with finasteride and doxazosin in men with lower urinary tract symptoms and clinical evidence of benign prostatic hyperplasia

1 reference

12 December 2020

Efficacy and safety of dutasteride in the four-year treatment of men with benign prostatic hyperplasia

1 reference

12 December 2020

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group

1 reference

12 December 2020

The efficacy of terazosin, finasteride, or both in benign prostatic hyperplasia. Veterans Affairs Cooperative Studies Benign Prostatic Hyperplasia Study Group

1 reference

12 December 2020

Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia

1 reference

12 December 2020

Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PREDICT) trial

1 reference

12 December 2020

Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride

1 reference

12 December 2020

Benign prostatic hyperplasia: a progressive disease of aging men.

1 reference

12 December 2020

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia

1 reference

12 December 2020

The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia

1 reference

12 December 2020

The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group

1 reference

12 December 2020

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC1472914&resulttype=core&format=json

10 May 2020

PubMed publication ID

16985923

1 reference